Literature DB >> 9359524

Initiation of contact system activation in plasma is dependent on factor XII autoactivation and not on enhanced susceptibility of factor XII for kallikrein cleavage.

F Citarella1, W A Wuillemin, Y T Lubbers, C E Hack.   

Abstract

Various mechanisms have been hypothesized to explain the initiation of contact system activation in plasma. We investigated the capability of dextran sulphate (DS) of different molecular weights to initiate contact system activation in normal human plasma, and compared this with their capability to support factor XII autoactivation and to enhance factor XII susceptibility for cleavage by kallikrein. Dextran sulphate of Mr 500,000 (DS500) and 50,000 (DS50) was able to initiate contact system activation in plasma (determined by measuring the amount of factor XIIa-C1-inhibitor, kallikrein-C1-inhibitor and factor XIa-C1-inhibitor complexes generated) as well as to support factor XII autoactivation and to enhance factor XII susceptibility for cleavage by kallikrein (as measured with amidolytic assays using purified proteins). In contrast, dextran sulphate of Mr 15,000 (DS15) and 5000 (DS5) neither induced contact system activation in plasma, nor supported autoactivation of factor XII, although both of these DS species enhanced the rate of activation of factor XII by kallikrein in the purified system. Based on these properties (i.e. binding of factor XII without inducing autoactivation), DS15 and DS5 were predicted to be inhibitors of contact system activation induced in plasma by DS500, which indeed was observed. We conclude that enhanced factor XII susceptibility for kallikrein activation and factor XII autoactivation are distinct phenomena, the latter being necessary to support activation of the contact system in plasma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9359524     DOI: 10.1046/j.1365-2141.1997.3513165.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  8 in total

Review 1.  The initiation and effects of plasma contact activation: an overview.

Authors:  Lisha Lin; Mingyi Wu; Jinhua Zhao
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

2.  A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation.

Authors:  Zonne L M Hofman; Chantal C Clark; Wariya Sanrattana; Aziz Nosairi; Naomi M J Parr; Minka Živkovic; Karoline Krause; Niklas A Mahnke; Jörg Scheffel; C Erik Hack; Marcus Maurer; Steven de Maat; Coen Maas
Journal:  J Biol Chem       Date:  2019-11-26       Impact factor: 5.157

Review 3.  In vivo roles of factor XII.

Authors:  Thomas Renné; Alvin H Schmaier; Katrin F Nickel; Margareta Blombäck; Coen Maas
Journal:  Blood       Date:  2012-09-19       Impact factor: 22.113

4.  Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.

Authors:  R S Woodruff; Y Xu; J Layzer; W Wu; M L Ogletree; B A Sullenger
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

Review 5.  Pathophysiology of Hereditary Angioedema.

Authors:  Sonia Caccia; Chiara Suffritti; Marco Cicardi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2014-12-01       Impact factor: 1.349

6.  The effect of increasing the sulfation level of chondroitin sulfate on anticoagulant specific activity and activation of the kinin system.

Authors:  J Hogwood; A Naggi; G Torri; C Page; P Rigsby; B Mulloy; E Gray
Journal:  PLoS One       Date:  2018-03-01       Impact factor: 3.240

7.  Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation.

Authors:  My-Linh Ngo; Fakhri Mahdi; Dhaval Kolte; Zia Shariat-Madar
Journal:  J Inflamm (Lond)       Date:  2009-01-27       Impact factor: 4.981

Review 8.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.

Authors:  Steven de Maat; Kusumam Joseph; Coen Maas; Allen P Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-06       Impact factor: 8.667

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.